0001439222-24-000010.txt : 20240109 0001439222-24-000010.hdr.sgml : 20240109 20240109162828 ACCESSION NUMBER: 0001439222-24-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240105 FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goff Brian CENTRAL INDEX KEY: 0001546216 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 24523603 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS, INC STREET 2: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wk-form4_1704835697.xml FORM 4 X0508 4 2024-01-05 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001546216 Goff Brian C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139 1 1 0 0 Chief Executive Officer 1 Common stock 2024-01-05 4 M 0 25527 0 A 52119 D Common stock 2024-01-09 4 S 0 12066 22.99 D 40053 D Performance share units 2024-01-05 4 M 0 25527 0 D Common stock 25527 119128 D Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022. Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. /s/ William Cook, as Attorney in Fact for Brian Goff 2024-01-09